This initiative is part of KFSHRC's efforts to foster innovation in healthcare, ensuring a reduction in the prevalence of genetic disorders and improving quality of life. It also reinforces the ...

“We are enthusiastic about getting patients started in the OCU200 Phase 1 clinical trial and sharing not only safety but preliminary efficacy data as the study progresses,” said Dr. Huma Qamar, Chief ...

This follows confirmation that no appeals were received against the Final Draft Guidance (FDG) recommendation announced on December 10, 2024. Following this, Santhera has already started launch ...

Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today announced plans to launch its validated flagship live cell ChemoFx® drug response assay in Europe and expanded ...

Micron Biomedical, a life science company developing the world’s first needle-free technology for drugs and vaccines that is based on dissolvable microarrays, today announced it secured more than $16 ...

Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 ...

Seres Therapeutics, Inc. (Nasdaq: MCRB) (Seres or the Company), a leading live biotherapeutics company, announced today the receipt of a $50 million installment payment related to the Company’s ...

ROCKVILLE, Md., Jan. 16, 2025 (GLOBE NEWSWIRE) -- The Inteleos Foundation, a global health nonprofit organization, has announced the selection of three recipients of the annual MedMissions Award, ...

Marks the Third Year Since the Launch of the First US Biosimilar Market Report; INCHEON, South Korea, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today released it ...

RIYADH, Saudia Arabia, Jan. 16, 2025 (GLOBE NEWSWIRE) -- We are advised by King Faisal Specialist Hospital & Research Centre that journalists and other readers should disregard the news release, “KFSH ...

The Company granted stock options to purchase up to an aggregate of 30,300 shares of EyePoint Pharmaceuticals common stock to four new employees. The stock options were granted on January 15, 2025.

Nusano isotope production to deliver breakthrough, 100X increase in global At-211 supply, and Atley’s radiopharmaceutical manufacturing technology to enable scalable At-211 radiopharmaceutical supply ...